pharma · Melanoma · HIV Infections
Bristol Myers Squibb
Bristol-Myers Squibb
Bristol-Myers Squibb is a pharma organization headquartered in STEINHAUSEN, CH. Primary therapeutic focus areas include Melanoma, HIV Infections, Prostate Cancer, Neoplasms by Site, Stomach Cancer. NovaPharmaNews links 4
3401 Princeton Pike, Lawrence Township, NJ 08648, US HQ
38,146 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- 3401 Princeton Pike, Lawrence Township, NJ 08648, US
- Employees
- 38,146
- Programs
- 40
- Drugs
- 17
- Patents
- 25
Deucravacitinib
Phase 3 · small molecule · Sjögren's Syndrome
Deucravacitinib for Sjögren's Syndrome is a Phase 3 program (small_molecule) at Bristol-Myers Squibb with 1 ClinicalTrials.gov record(s).
Internal code IM011-1069
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Bristol-Myers Squibb
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Sjögren's Syndrome
- Status
- active
- Trials
- 1